Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 41 out of 100. Cognitive tests and assessment

Topic: Amyloid, tau and blood-test diagnosis

Plain-language summary

Among 42 participants (median age: 71 years, 66.7% female), 26 (61.9%) were classified as progressors. Median (IQR) amyloid PET centiloid levels (56.7 [33.0-102.0] vs. 16.1 [5.3-61.3], p = 0.026) and Tau PET SUVR for Braak stages 3-4 (1.5 [1.2-2.1] vs. 1.1 [1.0-1.2], p <0.001) were significantly higher in progressors. Plasma p-Tau-217 (11.1 [7.1-21.0] vs. 4.0 [2.4-9.6] pg/mL, p = 0.004) and GFAP levels (206.7 [140.6-322.0] vs. 114.5 pg/mL [92.6-192.7], p = 0.003) were also significantly higher in progressors, while plasma p-Tau-181 and NfL levels showed no significant differences between groups (Figure 1). Tau PET SUVR provided the best prognostic value for 24-month progression (AUC 0.84, 95% CI 0.71-0.96), followed by plasma GFAP (AUC 0.78, 95% CI 0.62-0.94) and plasma p-Tau-217 (AUC 0.77, 95% CI 0.61-0.92) (Figure 2). Tau PET SUVR in Braak stages 3-4 is a robust marker for short-term cognitive and/or functional deterioration. Plasma p-Tau-217 not only serves a diagnosis but also has prognostic capabilities. Plasma GFAP outperforms plasma NfL in predicting short-term progression. Future studies should focus on the value of these biomarkers in long-term progression.

What this study adds

Evidence grade: Low

The record lists 42 participants. In 42 participants with mild cognitive impairment or mild dementia, higher tau PET, amyloid PET, plasma p-tau-217 and plasma GFAP were linked to progression over 24 months. Reported effect size: 66.7%; 61.9%; AUC 0.84.

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Booncharoen, K., Hiransuthikul, A., Likitjaroen, Y., Phanthumchinda, K., Thanprasertsuk, S., & Thanapornsangsuth, P. (2025). PET and Blood Biomarkers as Predictors of Short‐Term Progression in MCI and Mild Dementia: Prospective Insights from a Southeast Asian Middle‐Income Country. Alzheimer s & Dementia. https://doi.org/10.1002/alz70856_100227

Vancouver

Booncharoen K, Hiransuthikul A, Likitjaroen Y, Phanthumchinda K, Thanprasertsuk S, Thanapornsangsuth P. PET and Blood Biomarkers as Predictors of Short‐Term Progression in MCI and Mild Dementia: Prospective Insights from a Southeast Asian Middle‐Income Country. Alzheimer s & Dementia. 2025. doi:10.1002/alz70856_100227. PMID: 41447122.

BibTeX

@article{booncharoen2025-41447122,
  author  = {Booncharoen, Kittithatch and Hiransuthikul, Akarin and Likitjaroen, Yuttachai and Phanthumchinda, Kammant and Thanprasertsuk, Sekh and Thanapornsangsuth, Poosanu},
  title   = {{PET and Blood Biomarkers as Predictors of Short‐Term Progression in MCI and Mild Dementia: Prospective Insights from a Southeast Asian Middle‐Income Country}},
  journal = {Alzheimer s \& Dementia},
  year    = {2025},
  doi     = {10.1002/alz70856_100227},
  pmid    = {41447122},
  url     = {https://doi.org/10.1002/alz70856_100227}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.

Key findings

Why it matters

In 42 participants with mild cognitive impairment or mild dementia, higher tau PET, amyloid PET, plasma p-tau-217 and plasma GFAP were linked to progression over 24 months. These markers may help predict short-term decline, but the study is small and did not test any treatment.

Study details

How this study scored 41/100
How this study's score is builtJournal tier 7 of 10; Journal's citation record 2 of 4; Study design 0 of 12; Strength of evidence 1 of 5; Peer-review validation 10 of 10; How recent 4 of 5; Sample size 1 of 4; Effect reported 3 of 3; Studied in people 3 of 3; Randomized / blinded 0 of 2; Times cited 1 of 7; Citations per year 0 of 5; Impact for its field and year 1 of 6; Cited by studies here 0 of 6; Still being cited 0 of 4; Senior author's track record 1 of 4; Institution's track record 1 of 3; Multicenter collaboration 2 of 3; Indexed in PubMed 2 of 2; Free to read 2 of 2. Total 41 of 100.41 of 100 points earned59 not earned

Published in a peer-reviewed journal. Scored zero for study design and randomized / blinded because the record does not state it.

ComponentPointsWhy
Journal tier 7 / 10 Tier 3 — peer-reviewed journal (Alzheimer s & Dementia)
Journal's citation record 2 / 4 Alzheimer s & Dementia: journal h-index 228 (OpenAlex, 2026-10-29)
Study design 0 / 12 No study design recorded — scores zero, not guessed (not stated in the record — scored 0)
Strength of evidence 1 / 5 Rated “low” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 4 / 5 2025 — within 3 year(s) of the newest study here
Sample size 1 / 4 42 participants
Effect reported 3 / 3 Effect reported with a statistic (interval, p-value, ratio or similar)
Studied in people 3 / 3 Studied in people (participant count stated)
Randomized / blinded 0 / 2 No randomization or blinding stated — scores zero (not stated in the record — scored 0)
Times cited 1 / 7 Cited 1 times (OpenAlex, 2026-10-10)
Citations per year 0 / 5 0.3 citations a year over 3 year(s) since 2025
Impact for its field and year 1 / 6 Cited 0.6× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 0 / 6 No other study in this library cites it
Still being cited 0 / 4 Cited 1 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 1 / 4 Last-listed author Poosanu Thanapornsangsuth: h-index 5 (OpenAlex, whole career)
Institution's track record 1 / 3 World Health Organization: institution h-index 916 (OpenAlex)
Multicenter collaboration 2 / 3 OpenAlex lists 5 institution(s) in 2 countries
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 41447122)
Free to read 2 / 2 Free to read
Total 41 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Studies in the library that share something with this one. The line above each title says what.

Related studies in Cognitive tests and assessment from nearby years

Also tagged “cerebrospinal”

820 studies in the library carry the topic tag “cerebrospinal”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 820 tagged studies.

Studies sharing this one's topic tags

Similar studies

More on Cognitive tests and assessment

See all studies in Cognitive tests and assessment →